Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 23Leukemia 13Leukemia, Myeloid, Chronic-Phase 11Gastrointestinal Stromal Tumors 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Myeloproliferative Disorders 4Neoplasms 3Neoplasm Metastasis 3Melanoma 3Leukemia, Myeloid, Accelerated Phase 3Leukemia, Myeloid 3Blast Crisis 3Thyroid Neoplasms 2Prostatic Neoplasms 2Primary Myelofibrosis 2Pancreatic Neoplasms 2Myelodysplastic Syndromes 2Lung Neoplasms 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hematologic Neoplasms 2Glioblastoma 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Brain Neoplasms 2Bone Marrow Diseases 2Uterine Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Thrombocytosis 1Thrombocythemia, Essential 1

Interventions

pazopanib 2thymoglobulin 1sapanisertib 1pexidartinib 1pembrolizumab 1fludarabine phosphate 1Trabectedin 1Thiotepa 1Tacrolimus 1Stem Cell Transplantation 1Sirolimus 1Radiotherapy, Intensity-Modulated 1Polymerase Chain Reaction 1Neoadjuvant Therapy 1Mycophenolic Acid 1Melphalan 1Imatinib Mesylate 1Gene Expression Profiling 1Etoposide 1Doxorubicin 1Docetaxel 1Cyclosporins 1Cyclosporine 1Blotting, Western 1Antilymphocyte Serum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Neurofibrosarcoma × Imatinib Mesylate × Clear all
NCT00427583 2012-08-07

Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors

Novartis

Phase 2/3 Terminated
11 enrolled
CNSSarcoma

Neurofibromatoses, Nerve Sheath Neoplasms, Neurofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡